Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Top tierWe are a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. Our technology platform and differentiated human datasets enable us to identify promising targets based on insights into molecular changes that drive aging. In January 2025, we announced the nomination of our lead program, BGE-102, a potent, structurally novel, orally available, brain-penetrant small-molecule NLRP3 inhibitor.
In the company’s own words · 10-K filed Mar 24, 2026 · SEC EDGAR
BioAge Labs, Inc. (BIOA) reported revenue of $2.8M in Q1 2026 (quarter ended March 31, 2026), up 91% from the same quarter a year earlier. That came with net loss of $22M. For the full year FY2025, revenue was $9.0M and net income −$81M.
Raw charts
9 series · TTMAs reported to the SEC, without any scoring.
Drug Manufacturers - Specialty & Generic
The closest names by size in the same industry